Literature DB >> 15623824

Nutrition and aberrant DNA methylation patterns in atherosclerosis: more than just hyperhomocysteinemia?

Silvio Zaina1, Marie Wickström Lindholm, Gertrud Lund.   

Abstract

Methylation is a reversible modification of DNA participating in epigenetic regulation of gene expression. It is now clear that atherosclerosis is associated with aberrant DNA methylation patterns in the vascular tissue and peripheral blood cells, but the origin of this anomaly is poorly understood. Based on evidence that global DNA hypomethylation coexists with hyperhomocysteinemia in advanced human atherosclerosis, it is widely assumed that altered DNA methylation patterns in atherosclerosis are mainly secondary to a decrease in factors essential for the synthesis of S-adenosyl methionine (SAM, the main methyl group donor in DNA methylation reactions), such as folate and vitamin B-12, or to homocysteine-induced blocking of SAM biosynthesis. Nonetheless, recent work expanded this view by showing that both local DNA hyper- and hypomethylation occur in early atherosclerosis in normohomocysteinemic mice and that atherogenic lipoprotein profiles promote DNA hypermethylation in cultured human macrophages. These findings suggest that during early atherosclerosis, nutritional factors affect DNA methylation patterns by mechanisms that are likely to be independent of vitamin or homocysteine levels. These data have the potential to assist in the identification of preventive or therapeutic avenues for cardiovascular disease.

Entities:  

Mesh:

Year:  2005        PMID: 15623824     DOI: 10.1093/jn/135.1.5

Source DB:  PubMed          Journal:  J Nutr        ISSN: 0022-3166            Impact factor:   4.798


  45 in total

Review 1.  Epigenetic programming and risk: the birthplace of cardiovascular disease?

Authors:  Maria Cristina Vinci; Gianluca Polvani; Maurizio Pesce
Journal:  Stem Cell Rev Rep       Date:  2013-06       Impact factor: 5.739

Review 2.  Epigenetics and human disease: translating basic biology into clinical applications.

Authors:  David Rodenhiser; Mellissa Mann
Journal:  CMAJ       Date:  2006-01-31       Impact factor: 8.262

3.  Maternal inheritance, epigenetics and the evolution of polyandry.

Authors:  Jeanne A Zeh; David W Zeh
Journal:  Genetica       Date:  2007-08-20       Impact factor: 1.082

Review 4.  DNA hypomethylation in the origin and pathogenesis of human diseases.

Authors:  Igor P Pogribny; Frederick A Beland
Journal:  Cell Mol Life Sci       Date:  2009-03-27       Impact factor: 9.261

Review 5.  Epigenetic mechanisms in diabetic vascular complications.

Authors:  Marpadga A Reddy; Rama Natarajan
Journal:  Cardiovasc Res       Date:  2011-01-25       Impact factor: 10.787

6.  Overexpression of S-adenosylhomocysteine hydrolase (SAHH) in esophageal squamous cell carcinoma (ESCC) cell lines: effects on apoptosis, migration and adhesion of cells.

Authors:  Qinghua Li; Lihong Mao; Ruili Wang; Liqiang Zhu; Lexun Xue
Journal:  Mol Biol Rep       Date:  2014-01-16       Impact factor: 2.316

7.  Relationship of impairment induced by intracellular S-adenosylhomocysteine accumulation with DNA methylation in human umbilical vein endothelial cells treated with 3-deazaadenosine.

Authors:  Xiaoping Yu; Wenhua Ling; Mantian Mi
Journal:  Int J Exp Pathol       Date:  2009-12       Impact factor: 1.925

8.  S-adenosyl homocysteine hydrolase (SAHH) accelerates flagellar regeneration in Dunaliella salina.

Authors:  Qinghua Li; Liqiang Zhu; Yunmeng Yan; Dandan Chai; Jie Li; Lexun Xue
Journal:  Curr Microbiol       Date:  2013-03-27       Impact factor: 2.188

9.  DNA methylation as a biomarker for cardiovascular disease risk.

Authors:  Myungjin Kim; Tiffany I Long; Kazuko Arakawa; Renwei Wang; Mimi C Yu; Peter W Laird
Journal:  PLoS One       Date:  2010-03-15       Impact factor: 3.240

10.  Hypothesis: a unifying mechanism for nutrition and chemicals as lifelong modulators of DNA hypomethylation.

Authors:  Duk-Hee Lee; David R Jacobs; Miquel Porta
Journal:  Environ Health Perspect       Date:  2009-07-08       Impact factor: 9.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.